A novel coronavirus with a characteristic crown morphology at scanning electron microscopy, causing coronavirus disease 2019 (COVID-19) that is spread by human-to-human transmission due to close contacts, was identified in China and announced by the World Health Organization (WHO) as a pandemic on Mar 11, 2020 (
1). No specific antiviral drugs are available to treat COVID-19; thus, early detection and adherence to medical isolation are crucial (
2). To date, computerized tomography (CT) images are used by physicians for a fast and effective diagnosis of COVID-19 (
3). Based on the literature, patchy ground-glass opacities with interlobular septal and vascular thickening, consolidative opacities with a rounded pattern, and a peripheral distribution are the basic findings of COVID-19 in chest CT (
4). These findings are helpful to the radiologist in the early detection and diagnosis of patients. Early disease recognition can speed up treatments and prompt rapid patient isolation (
5). Chest CT cannot alone fully exclude the diagnosis of COVID-19, particularly in the early stage of the infection (
3,
4). Because of the prodromal phase of COVID-19, viral infection manifests with symptoms before the emergence of imaging manifestations (
6). A normal chest CT scan does not exclude the diagnosis, and also CT findings can vary as pneumonia progresses (
4,
5). The data of CT findings for COVID-19 in the literature indicate similar features to the other coronaviruses (severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) (
7). The diagnosis of COVID-19 with CT scan is more sensitive than the initial reverse transcription-polymerase chain reaction (RT-PCR) and is also relatively simple and quick (
8). Because of its invasiveness and objectivity, CT scan is also used to follow up patients with COVID-19. Although the chest CT examination plays a crucial role in the initial diagnosis of COVID-19, the relationship between the initial CT findings, including the extent of the involvement, and mortality and length of stay in hospital has not well been documented yet.
The neutrophil-lymphocyte ratio (NLR) was known as an indicator of inflammatory status, and a higher level of NLR in a patient with COVID-19 has been proved as a risk factor of mortality (
9,
10). The negative outcomes of COVID-19 were found to be associated with a higher NLR, mostly an NLR of > 3.13 (
11). Thus, the higher NLR levels were known as an indicator of the severity of COVID-19 as well as a hyperinflammatory state (
11). However, the counts of neutrophil, NLR, and lymphocyte have not been studied in detail to compare the extent of lung involvement in CT. Furthermore, the association of mortality with the extent of lung involvement in the initial CTs of patients diagnosed with COVID-19 has not well been documented in the literature.